Characterisation, structural investigations and biological activity of substitute d salicylidene-base d compounds

Seven salicylidene base compounds ( 1 - 7 ), p-NO2-SalH-R, (R=halogen, hydroxyl, or nitro group on ei- ther the para (p-) or ortho (o-) position); were prepared by condensing 2-hydroxy-5-nitrobenzaldehyde with p-hydroxyaniline ( 1 ), p-nitroaniline ( 2 ), p-fluoroaniline ( 3 ), p-chloroaniline ( 4 ), p-bromoaniline ( 5 ) o-fluoroaniline ( 6 ) and o-hydroxyaniline ( 7 ), to form the respective ligands ( 1 - 7 ). The compounds were fully characterised via1 H and 13 C NMR, IR, UV/Vis, and elemental analysis. Luminescence studies were performed and single crystals, suitable for X-ray diffraction, were obtained for four of the compounds. The compounds were assayed for cytotoxicity against human breast adenocarcinoma (MCF-7), human cervical cancer (HeLa), human lung adenocarcinoma (A549), liver hepatocellular carcinoma (HepG2), human col- orectal adenocarcinoma (Caco-2) and African green monkey kidney (Vero) cell lines and for antibacterial activity against 3 nosocomial pathogenic bacteria ( E. coli, E. faecalis, and S. aureus) to correlate between structural variations and bioactivity. Compound 2 showed anticancer activity against MCF-7 and HepG2 cell lines with LC50 values of 48.78 mu M and 59.26 mu M, respectively. Compound 7 exhibited anticancer activity against HeLa and A549 cell lines with LC50 values of 50.27 mu M and 37.88 mu M, respectively. Com- pounds 4 and 5 demonstrated anticancer activity against the MCF-7 cell line with LC50 values of 48.04 mu M and 56.58 mu M, respectively. The compounds showed no antibacterial activity against the three tested nosocomial pathogenic bacterial strains.(c) 2022 Elsevier B.V. All rights reserved.